- Home
- INSW vs IMVT Comparison
INSW vs IMVT Comparison
Compare INSW & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- IMVT
- Stock Information
- Founded
- INSW 1999
- IMVT 2018
- Country
- INSW United States
- IMVT United States
- Employees
- INSW N/A
- IMVT N/A
- Industry
- INSW Semiconductors
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSW Technology
- IMVT Health Care
- Exchange
- INSW Nasdaq
- IMVT Nasdaq
- Market Cap
- INSW 2.3B
- IMVT 2.7B
- IPO Year
- INSW N/A
- IMVT N/A
- Fundamental
- Price
- INSW $44.79
- IMVT $17.41
- Analyst Decision
- INSW Buy
- IMVT Buy
- Analyst Count
- INSW 2
- IMVT 9
- Target Price
- INSW $52.00
- IMVT $27.71
- AVG Volume (30 Days)
- INSW 495.9K
- IMVT 1.7M
- Earning Date
- INSW 11-06-2025
- IMVT 11-06-2025
- Dividend Yield
- INSW 7.31%
- IMVT N/A
- EPS Growth
- INSW N/A
- IMVT N/A
- EPS
- INSW 4.81
- IMVT N/A
- Revenue
- INSW $798,838,000.00
- IMVT N/A
- Revenue This Year
- INSW N/A
- IMVT N/A
- Revenue Next Year
- INSW $5.23
- IMVT N/A
- P/E Ratio
- INSW $9.30
- IMVT N/A
- Revenue Growth
- INSW N/A
- IMVT N/A
- 52 Week Low
- INSW $27.20
- IMVT $12.72
- 52 Week High
- INSW $50.40
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- INSW 46.85
- IMVT 58.24
- Support Level
- INSW $42.26
- IMVT $16.77
- Resistance Level
- INSW $45.06
- IMVT $17.84
- Average True Range (ATR)
- INSW 1.26
- IMVT 0.81
- MACD
- INSW -0.32
- IMVT 0.14
- Stochastic Oscillator
- INSW 51.64
- IMVT 63.24
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.